近日，微創醫療(00853)在資本市場表現活躍，現漲超4%，截至發稿，漲幅達3.33%，報11.49港元，成交額1.55億港元。
美銀證券發佈的研報，爲微創醫療的股價上漲提供了有力支撐。研報重申對微創醫療“買入”評級，原因在於其風險回報具吸引力。公司擁有多元化的高價值耗材產品組合，其中手術機器人業務更是被視爲未來關鍵增長動力。美銀證券預期，手術機器人業務於2034年將貢獻19%的總收入、。
此外，研報還指出，微創醫療股東上實集團可能會爲公司提供財務及業務支持，並着手優化公司的治理架構。同時，公司正在積極化解流動性憂慮，通過成本控管及處置非核心資產等舉措，有望自2026年上半年起實現盈利。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments